Evidence map›Paper›PMID 26681446›Full record

ArticlePLoS genetics2015

GDNF Overexpression from the Native Locus Reveals its Role in the Nigrostriatal Dopaminergic System Function.

Anmol Kumar, Jaakko Kopra, Kärt Varendi, Lauriina L Porokuokka, Anne Panhelainen, Satu Kuure, Pepin Marshall, Nina Karalija, Mari-Anne Härma, Carolina Vilenius and 14 more

Erratum issuedOpen access · goldAbstract read
In one paragraph

Article in PLoS genetics, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 72 papers.

0numbers the graph read from it
0cells of the map it votes in
72citing papers in PubMed
5.2field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

72 citing papers in PubMed, 122 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Review
  13. Article
  14. Review
  15. Article
  16. Heliyon · 2023
    Article
  17. Review
  18. Article
  19. Article
  20. Article

12 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

24 authors at 3 institutions in 3 countries.

Anmol KumarInstitute of Biotechnology, University of Helsinki, Helsinki, Finland.
Jaakko KopraDivision of Pharmacology and Pharmacotherapy, Faculty of Pharmacy, University of Helsinki, Helsinki, Finland.
Kärt VarendiInstitute of Biotechnology, University of Helsinki, Helsinki, Finland.
Lauriina L PorokuokkaInstitute of Biotechnology, University of Helsinki, Helsinki, Finland.
Anne PanhelainenInstitute of Biotechnology, University of Helsinki, Helsinki, Finland.
Satu KuureInstitute of Biotechnology, University of Helsinki, Helsinki, Finland.
Pepin MarshallInstitute of Biotechnology, University of Helsinki, Helsinki, Finland.
Nina KaralijaDepartment of Histology and Cell Biology, Umeå University, Umeå, Sweden.
Mari-Anne HärmaInstitute of Biotechnology, University of Helsinki, Helsinki, Finland.
Carolina VileniusInstitute of Biotechnology, University of Helsinki, Helsinki, Finland.
Kersti LilleväliDepartment of Physiology, Institute of Biomedicine and Translational Medicine, University of Tartu, Tartu, Estonia.
Triin TekkoDepartment of Physiology, Institute of Biomedicine and Translational Medicine, University of Tartu, Tartu, Estonia.
Jelena MijatovicDivision of Pharmacology and Pharmacotherapy, Faculty of Pharmacy, University of Helsinki, Helsinki, Finland.
Nita PulkkinenDivision of Pharmacology and Pharmacotherapy, Faculty of Pharmacy, University of Helsinki, Helsinki, Finland.
Madis JakobsonDepartment of Biochemistry and Developmental Biology, Institute of Biomedicine, University of Helsinki, Helsinki, Finland.
Maili JakobsonInstitute of Biotechnology, University of Helsinki, Helsinki, Finland.
Roxana OlaDepartment of Biochemistry and Developmental Biology, Institute of Biomedicine, University of Helsinki, Helsinki, Finland.
Erik PalmInstitute of Biotechnology, University of Helsinki, Helsinki, Finland.
Maria LindahlInstitute of Biotechnology, University of Helsinki, Helsinki, Finland.
Ingrid StrömbergDepartment of Histology and Cell Biology, Umeå University, Umeå, Sweden.
Vootele VõikarNeuroscience Center and Department of Biological and Environmental Sciences, University of Helsinki, Helsinki, Finland.
T Petteri PiepponenDivision of Pharmacology and Pharmacotherapy, Faculty of Pharmacy, University of Helsinki, Helsinki, Finland.
Mart SaarmaInstitute of Biotechnology, University of Helsinki, Helsinki, Finland.
Jaan-Olle AndressooInstitute of Biotechnology, University of Helsinki, Helsinki, Finland.
University of Helsinki · FIUmeå University · SEUniversity of Tartu · EE

Funding

NINDS NIH HHS NS 0708259
6 · The paper itself

Abstract

Degeneration of nigrostriatal dopaminergic system is the principal lesion in Parkinson's disease. Because glial cell line-derived neurotrophic factor (GDNF) promotes survival of dopamine neurons in vitro and in vivo, intracranial delivery of GDNF has been attempted for Parkinson's disease treatment but with variable success. For improving GDNF-based therapies, knowledge on physiological role of endogenous GDNF at the sites of its expression is important. However, due to limitations of existing genetic model systems, such knowledge is scarce. Here, we report that prevention of transcription of Gdnf 3'UTR in Gdnf endogenous locus yields GDNF hypermorphic mice with increased, but spatially unchanged GDNF expression, enabling analysis of postnatal GDNF function. We found that increased level of GDNF in the central nervous system increases the number of adult dopamine neurons in the substantia nigra pars compacta and the number of dopaminergic terminals in the dorsal striatum. At the functional level, GDNF levels increased striatal tissue dopamine levels and augmented striatal dopamine release and re-uptake. In a proteasome inhibitor lactacystin-induced model of Parkinson's disease GDNF hypermorphic mice were protected from the reduction in striatal dopamine and failure of dopaminergic system function. Importantly, adverse phenotypic effects associated with spatially unregulated GDNF applications were not observed. Enhanced GDNF levels up-regulated striatal dopamine transporter activity by at least five fold resulting in enhanced susceptibility to 6-OHDA, a toxin transported into dopamine neurons by DAT. Further, we report how GDNF levels regulate kidney development and identify microRNAs miR-9, miR-96, miR-133, and miR-146a as negative regulators of GDNF expression via interaction with Gdnf 3'UTR in vitro. Our results reveal the role of GDNF in nigrostriatal dopamine system postnatal development and adult function, and highlight the importance of correct spatial expression of GDNF. Furthermore, our results suggest that 3'UTR targeting may constitute a useful tool in analyzing gene function.

Indexed as

AcetylcysteineAnimalsCentral Nervous SystemDisease Models, AnimalDopamineDopaminergic NeuronsGene Expression Regulation, DevelopmentalGlial Cell Line-Derived Neurotrophic FactorHumansKidneyMiceNeostriatumNeuroprotective AgentsParkinson Disease, SecondarySubstantia NigraAcetylcysteineDopamineGdnf protein, mouseGlial Cell Line-Derived Neurotrophic FactorlactacystinNeuroprotective Agents

Identifiers

PMID26681446
PMCPMC4682981
OpenAlexW2215748303

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.